1. Home
  2. SCCO vs REGN Comparison

SCCO vs REGN Comparison

Compare SCCO & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern Copper Corporation

SCCO

Southern Copper Corporation

HOLD

Current Price

$144.25

Market Cap

82.0B

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$751.07

Market Cap

73.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCCO
REGN
Founded
1952
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.0B
73.9B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
SCCO
REGN
Price
$144.25
$751.07
Analyst Decision
Hold
Buy
Analyst Count
9
23
Target Price
$120.59
$795.74
AVG Volume (30 Days)
1.2M
1.1M
Earning Date
10-28-2025
02-03-2026
Dividend Yield
2.51%
0.47%
EPS Growth
25.54
2.88
EPS
4.67
41.59
Revenue
$12,334,600,000.00
$14,247,800,000.00
Revenue This Year
$12.82
$1.95
Revenue Next Year
$4.89
$5.47
P/E Ratio
$30.46
$17.82
Revenue Growth
12.70
2.89
52 Week Low
$72.75
$476.49
52 Week High
$149.75
$790.98

Technical Indicators

Market Signals
Indicator
SCCO
REGN
Relative Strength Index (RSI) 62.28 60.96
Support Level $141.84 $689.88
Resistance Level $149.75 $753.61
Average True Range (ATR) 3.73 20.54
MACD 1.00 -4.36
Stochastic Oscillator 75.38 60.95

Price Performance

Historical Comparison
SCCO
REGN

About SCCO Southern Copper Corporation

Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: